title: Blockade and reversal of spinal morphine tolerance by P2X3 receptor antagonist.
abstract: In recent years, studies have substantiated the view that P2X3 receptors play a part in the generation and transmission of purinergic signals in inflammatory and chronic neuropathic pain. Data have also been presented to suggest that the process of P2X3 receptor antagonism inhibits inflammatory hyperalgesia, involving the spinal opioid system. The aim of this study was to investigate the effect of the selective P2X3 receptor antagonist A-317491 on the development of antinociceptive tolerance to chronic morphine administration in mice. Daily systemic injection of A-317491 attenuated the morphine-induced antinociceptive tolerance to von Frey and thermal stimuli. Repeated morphine injections alone led to a significant rightward shift in the morphine dose-response curve compared with that with A-317491. A single dose of A-317491 also showed a reversal effect in morphine-tolerant mice. In a withdrawal test, co-administration of A-317491 and morphine also reduced the naloxone-induced withdrawal symptoms compared with the morphine-alone group. Thus, we propose that the P2X3 receptor is involved in the process of morphine antinociceptive tolerance and may be a new therapeutic target in the prevention of tolerance to morphine-induced antinociception.
authors.affiliation: Department of Anesthesiology, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
authors.forename: Xiaqing
authors.initials: X
authors.lastname: Ma
authors.forename: Tao
authors.initials: T
authors.lastname: Xu
authors.forename: Hao
authors.initials: H
authors.lastname: Xu
authors.forename: Wei
authors.initials: W
authors.lastname: Jiang
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology*; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010146:Pain / Q000188:drug therapy; D010636:Phenols / Q000008:administration & dosage / Q000494:pharmacology*; D011083:Polycyclic Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D058920:Purinergic P2X Receptor Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D058477:Receptors, Purinergic P2X3 / Q000187:drug effects* / Q000378:metabolism; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism; D013375:Substance Withdrawal Syndrome
chemical_list: C470346:A-317491; D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D010636:Phenols; D011083:Polycyclic Compounds; D058920:Purinergic P2X Receptor Antagonists; D058477:Receptors, Purinergic P2X3; D009270:Naloxone; D009020:Morphine